OptimizeRx Corp

OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

OptimizeRx Corp exceeds revenue expectations, eyes growth through strategic deals

OptimizeRx Corp's strong revenue performance and focus on Real-World Data deals position them for growth despite challenges in revenue retention and operating expenses.
The company's strategic initiatives, including share repurchase, capacity utilization, and omnichannel expansion, showcase resilience and potential for market capture.
By leveraging RWD-AI models, focusing on strategic partnerships, and expanding service offerings, OptimizeRx aims to achieve financial and operational goals in 2023.

OptimizeRx Corp reports solid Q1 performance and eyes growth opportunities

OptimizeRx Corp (OPRX) reported solid Q1 performance, meeting revenue expectations and maintaining full-year outlook with a 10% YoY increase expected. The company showcased strengths in strategic partnerships, RWD-AI solutions, and effective use cases for RWE products.
Despite challenges in operating expenses and net revenue retention rate decline, the company is focused on innovation and growth opportunities through M&A, technology investments, and service expansion. By addressing challenges and leveraging opportunities, OptimizeRx Corp aims for sustainable growth and market differentiation.
With a strong emphasis on product execution, customer ROI, and shareholder value enhancement through a share repurchase program, OptimizeRx Corp is positioning itself for continued success in the healthcare technology sector. The company's strategic initiatives and focus on revenue diversification signal a promising outlook for future growth.

OptimizeRx Corp reports Q2 results, focuses on AI growth

OptimizeRx Corp navigated challenges in Q2 2023 with a focus on financial stability, operational efficiency, and strategic growth initiatives.
Despite disappointment with results, the company remains optimistic about the future of digital marketing in healthcare and the potential of AI-driven solutions.
With a strong balance sheet, emphasis on core business areas, and plans for cost management, OptimizeRx is positioned to capitalize on growth opportunities.
The company's commitment to renewals, upsells, and AI-driven engagement underscores a proactive approach to revenue retention and customer satisfaction.

OptimizeRx Corp (OPRX) beats Q3 expectations, eyes robust 2024 growth

OptimizeRx's Q3 performance exceeded expectations, showcasing strong financials and strategic acquisitions driving growth. While competitors face challenges, OptimizeRx is poised for further expansion and revenue increase in 2024 through enhanced platforms and market opportunities.

OptimizeRx Corp exceeds revenue expectations, eyes $100M target in 2024

OptimizeRx Corp delivered exceptional Q4 2023 results, driven by organic messaging strength and the Medicx Health acquisition.
The company's focus on digital solutions and strategic partnerships positions it well for future growth and capturing pharma spend.
While facing macroeconomic challenges, OptimizeRx's progress in Medicx Health integration and DAAP platform growth present promising opportunities.

OptimizeRx Corp reports robust Q1 performance, eyes sustained growth

OptimizeRx Corp's Q1 2024 performance reflects strong revenue growth, improved gross margin, and positive operating cash flow, underpinned by a focus on DAAP and stakeholder engagement.
While facing challenges in profitability and seasonality impact, the company remains optimistic about scaling DAAP, accelerating revenue growth, and enhancing performance in the second half of the year.
With opportunities to drive revenue through cross-selling, expanding infrastructure, and leveraging AI models, OptimizeRx is poised for sustainable growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Analysis demonstrates effectiveness of OptimizeRx's real-world evidence solution to identify patients suitable for a specialty therapy within a narrow timeframe Analysis demonstrates effectiveness of OptimizeRx's real-world evidence solution to identify patients suitable for a specialty therapy within a narrow timeframe

OptimizeRx Announces Strong Results from its use of Previously Announced AI/RWE Solution

Analysis finds patent-pending real-world evidence solution successful in identifying HCPs with patients at risk of non-adherence due to unexpected cost.

OptimizeRx Reports Results of Flagship Evidence-Based Physician Engagement Program

OptimizeRx Corporation (NASDAQ:OPRX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Joy Zhang - SVB Securities Sean Dodge - RBC Capital Markets Eric Martinuzzi - Lake Street Marc Wiesenberger - B. Riley Securities Jeff Garro - Piper Sandler Operator Good afternoon, everyone.

OptimizeRx Corporation (OPRX) CEO William Febbo on Q2 2022 Results - Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -60% and 18.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Misses Q2 Earnings and Revenue Estimates

ROCHESTER, Mich., Aug. 09, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended June 30, 2022. Quarterly comparisons are to the same year-ago period.

UPDATE – OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense

ROCHESTER, Mich., Aug. 09, 2022 (GLOBE NEWSWIRE) --   OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended June 30, 2022. Quarterly comparisons are to the same year-ago period.

OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense

OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx Corp. (OPRX) Reports Next Week: What to Know Ahead of the Release

ROCHESTER, Mich., July 21, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, August 9, 2022, at 4:30 p.m. Eastern time to discuss its results for the second quarter, ended June 30, 2022. The financial results will be issued in a press release prior to the call.

OptimizeRx Sets Second Quarter Fiscal 2022 Conference Call for Tuesday, August 9 at 4:30 p.m. ET

Doximity

SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ: OPRX) with a buy rating and a price target of $38, implying an upside of 36%. The analysts say OptimizeRx is the largest EHR-embedded messaging network and enjoys a solid financial profile of 30%+ top-line growth.

SVB Leerink Sees 'Cheaper Way' To Pharma Digital Marketing With This Stock

OptimizeRx Corp. (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OptimizeRx Corp. (OPRX) Moves 8.9% Higher: Will This Strength Last?

Large and growing TAM with industry tailwinds like digitalization supporting growth in demand for OptimizeRx's solutions. Highly scalable operating model with more than sufficient network capacity to facilitate growth in the near term.

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

The latest omni-channel platform extension gives pharma access to up to 84% of prioritized HCPs on social media with content that is specific to their specialty The latest omni-channel platform extension gives pharma access to up to 84% of prioritized HCPs on social media with content that is specific to their specialty

OptimizeRx Brings Real-World Evidence-Driven Engagement Programs to Social Media With New Exclusive Partnership

Coursera

Flywire Corp

Sunnova Energy International Inc

CarParts.com, Inc.

Small-cap stocks are less liquid, more volatile, and have a lower market cap. But they also offer the opportunity for greater returns.

5 Small-Cap Stocks That Are Diamonds in the Rough

Celsius Holdings

Innovative Industrial Properties

ServiceNow

NVIDIA

Paylocity Hlds

PDC Energy Inc

SolarEdge Technologies

STAAR Surgical

Tandem Diabetes Care

Except for energy stocks, 2022 has been a very difficult year to find any equities able to perform well in these volatile markets. And high-growth stocks have been hit especially hard.

The 10 Best High-Growth Stocks to Buy

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy today announced that Mike Rousselle, vice president of data product, has been named one of the 2022 PM360 ELITE 100 in the Data Miners category. The PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represents the most influential people in the healthcare industry today.

OptimizeRx's Mike Rousselle Named One of 2022 PM360 ELITE 100

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that its Board of Directors has unanimously authorized a share repurchase program, under which OptimizeRx may repurchase up to $20 million of its outstanding common stock.

OptimizeRx Authorizes $20 Million Share Repurchase Program

ROCHESTER, Mich., May 10, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that management will participate in the RBC Healthcare Conference taking place in New York City on May 17-18, 2022, and the B. Riley Annual Institutional Conference happening in Beverly Hills, California on May 25-26, 2022.

OptimizeRx to Participate in Upcoming May Conferences

Affimed

Blueprint Medicines

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

3 Small-Caps That Might Be Acquisition Candidates

OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer & Chief Operating Officer Andrew D'Silva - Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Mark Wiesenberger - B. Riley Securities Max Michaelis - Lake Street Capital Markets Harvey Poppel - Poppel Operator Greetings.

OptimizeRx Corporation (OPRX) CEO William Febbo on Q1 2022 Results - Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates

ROCHESTER, Mich., May 04, 2022 (GLOBE NEWSWIRE) --  OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended March 31, 2022. Quarterly comparisons are to the same year-ago period.

OptimizeRx Reports First Quarter 2022 Financial Results, Revenue Up 22%, Successfully Completes EvinceMed Acquisition

ROCHESTER, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy has published its first Environmental, Social and Governance (ESG) report. The report details the Company's initiatives, performance, and strategies against key metrics to disclose the most significant economic, social, and environmental impacts that result from its activities. Aligned with the 21 core Stakeholder Capitalism Metrics across the four categories of Governance, Planet, People, and Prosperity, notable highlights reflected in the report reinforce the Company's commitment to ESG transparency and accountability.

OptimizeRx Releases First Environmental, Social and Governance (ESG) Report

Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline

ROCHESTER, Mich., April 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the results of a survey of 102 specialist physicians highlighting how inefficient access pathways negatively impact patient care. Specifically, the survey found on average that physicians would make a different therapy choice for 33% of patients if medication access was not a factor, and physicians had to change their treatment plan for 26% of patients due to medication access challenges.

UPDATE – Surveyed Physicians Say Access Challenges Impact Their Care Plans for up to 33% of Patients

ROCHESTER, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the results of a survey of 102 specialist physicians highlighting how inefficient access pathways negatively impact patient care. Specifically, the survey found that physicians would make a different therapy choice for one out of three patients if medication access was not a factor, and physicians had to change their treatment plan in one out of four patients due to medication access challenges.

News for OptimizeRx Corp Stock (OPRX)